


202


MAY-AUGUST 2023


% FUNDED



Orphan drugs are currently funded by the NHS

FUNDED IN SPAIN





13


AVERAGE WAITING TIME



28 Not funded by resolution Under study or without funding request

49 Orphan Drugs with NC not funded by the NHS

Months between



27%

6%

35%

2022

2023 -

Haematological agent

Hormonal preparations Dermatological

Musculoskeletal Immunomodulators Sense organs

16%

15%

APPROVALS

AND FUNDING 2015 - 2023

2021

2022

2023


Anti-infective

Oncology


Other

NUMBER OF ODS NOT FUNDED BY YEAR OF NC






WAITING TIME SINCE MA



ADVANCED THERAPIES WITH ORPHAN DESIGNATION



Note: For the preparation of this report it has not been possible to take into account drugs that are available in Spain under specific situations and special authorisations within the framework of Royal Decree 1015/2009 (compassionate use, use under conditions other than those authorised or access to foreign medicines), as the data were not available. *Aggregated data as at 31 August 2023

2019

NC



2016

2017

2018

MA

2015

aelmhu.es twitter.com/aelmhu 2020

NHS